Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I got in at 4.11 :)
sweet bounce for anyone that got in around 3.40; I wanted to but funds are all tied up right now
I wonder if a major holder had a stop loss get triggered....which triggered a bunch of others, and so on and so forth...this is ridiculous. You don't see things TANK over 50% AFTER a capital fund takes interest. Unless the conditions and limitations part is scaring people. May have to buy in here at these rock bottom prices
FUNDING: NuPathe Inc announced the entry into a common stock purchase agreement with Aspire Capital Fund, LLC, which provides that subject to certain conditions and limitations, Aspire has committed to purchase up to $30 million of NuPathe common stock over the next 24 months
Would love to know those terms and conditions - I am certain one of them related to the price of the stock... They have to be hating their inital 500K investment right now, but i guess this represents a good buying opp for them!
Mass sell off! Will we ever find the bottom?
Seriously what the heck is going on here??? This is in a death spiral the last four days and I see no reason for it to be declining THIS bad
I will take the blame, I took a position Friday...that happens a lot with my stocks
Why the hell has this thing tanked over the last 3 days??
I think $6.00 is reasonable target before FDA date...but I'll be out around 5.50ish
What kind of bounce are you looking for it to take? Short/Long and back up to where it was a couple of days ago or just 10% or so from here?
Thanks,
Sho-Nuff
I jumped in at 4.65
I just took a position in PATH, this is the type of market to watch the sector for big sell offs and take advantage of them. Bio tech stocks tend to have huge swings in markets like the current one we are in.....
Added to my position here today... Trying to catch a falling knife!
Sho-Nuff
AF tweeted negative comments about today's pr. I'm sure that didn't help. Shorts having fun with this one today.
I know, still holding, not selling at this level
So what? Some fund purchasing this at $7.07 per share and the stock drops?
Well, it will help us at tax time...keep waiting to see a bounce, so far just a splat no bounce
I sure am glad I got into PATH! I wasn't losing my money quick enough. PATH is taking care of that for me though!
SHO-NUFF
Just out. Sounds pretty good to me, but WDIK. Like to hear other opinions.
NuPathe Announces Common Stock Purchase Agreement for up to $30 Million
1 minutes ago - Marketwire via Comtex
MarketwireNuPathe Inc. (NASDAQ: PATH), a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders, today announced the entry into a common stock purchase agreement with Aspire Capital Fund, LLC, which provides that subject to certain conditions and limitations, Aspire has committed to purchase up to $30 million of NuPathe common stock over the next 24 months. Aspire made an initial investment of $500,000 by purchasing 70,721 shares of NuPathe common stock at a purchase price of $7.07 per share, representing a 19% premium to the closing market price on August 2, 2011.
"We intend to use this facility opportunistically to add to our balance sheet," said Jane H. Hollingsworth, chief executive officer of NuPathe. "Securing this facility furthers our goal of building our financial strength and flexibility as we continue to prepare for the expected launch of our migraine patch in the first half of 2012. Aspire Capital's decision to make an initial investment at a premium to the current market price shows confidence in NuPathe and our ability to execute. We look forward to bringing this innovative product to market for the millions of underserved migraine patients and particularly for those who suffer from migraine-related nausea."
As a result of its initial investment, Aspire's remaining purchase commitment under the facility is up to $29.5 million of NuPathe common stock.
During the two-year term of the purchase agreement, NuPathe will control the timing and amount of any sale of its common stock to Aspire, providing the Company with flexibility to utilize the facility as desired. Aspire has no right to require any sales by NuPathe, but is obligated to make purchases as NuPathe directs. Pricing of sales under the agreement will be determined each time the Company elects to sell shares to Aspire based upon a predetermined formula as set forth in the purchase agreement. A more complete and detailed description of the purchase agreement is set forth in the Company's current report on Form 8-K, filed today with the U.S. Securities and Exchange Commission.
The offer and sale of the shares of NuPathe's common stock issuable under the facility have not been registered under the Securities Act of 1933, as amended. Accordingly, these securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act. NuPathe has agreed to file within 10 business days a registration statement on Form S-1, covering the resale of the common stock issued and issuable in accordance with the terms of the facility.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.
About NP101 (Zelrix) NP101 (also known as Zelrix) is an active, single-use, transdermal sumatriptan patch being developed for the treatment of migraine. NP101 is designed to provide migraine patients fast onset and sustained relief through a tolerable, non-oral route of administration with low incidence of triptan-related adverse events including chest tightness, chest heaviness, numbness of the extremities, and paresthesias or tingling. NP101 may provide an attractive treatment option for millions of migraine patients because it avoids the need for oral administration. Many migraine patients delay or avoid treatment with oral medications as a result of underlying migraine-related nausea and vomiting. In addition, the absorption of oral medications may be compromised during a migraine, which may adversely affect the efficacy of such medications. NP101 is powered by SmartRelief(TM), NuPathe's proprietary transdermal delivery technology. SmartRelief consists of a controlled delivery technology that uses a mild electrical current to actively transport medication through the skin using a process called iontophoresis. NuPathe's New Drug Application (NDA) for NP101 is currently under review by the U.S. Food and Drug Administration with a Prescription Drug User Fee Act (PDUFA) date of August 29, 2011.
About NuPathe NuPathe Inc. (www.nupathe.com) is a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system including neurological and psychiatric disorders. NuPathe's lead product candidate, NP101, is an active, single-use, transdermal sumatriptan patch being developed for the treatment of migraine. In addition to NP101, NuPathe has two additional proprietary product candidates: NP201 for the continuous symptomatic treatment of Parkinson's disease, which the company plans to partner, and NP202 in preclinical development for the long-term treatment of schizophrenia and bipolar disorder.
Cautionary Note Regarding Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking statements for this purpose and include, among others, statements relating to: the extent to which we may utilize the purchase agreement as a source of funding; the ability to obtain, and timing of, FDA approval of Zelrix; the timing of the commercial launch of Zelrix; the potential benefits of, and market for, Zelrix; our plans to partner NP201; and the implications of Aspire Capital's decision to make an investment.
Forward-looking statements are based upon management's current expectations and beliefs and are subject to a number of risks, uncertainties and other factors that could cause actual results and events to differ materially from those indicated herein including, among others: NuPathe's ability to obtain marketing approval for and commercialize NP101; and the risks, uncertainties and other factors discussed in NuPathe's Annual Report on Form 10-K for the year ended December 31, 2010 under the caption "Risk Factors" and elsewhere in such report, which is available on NuPathe's website at www.nupathe.com in the "Investor Relations -- SEC Filings" section. While NuPathe may update certain forward-looking statements from time to time, it specifically disclaims any obligation to do so, whether as a result of new information, future developments or otherwise. You are cautioned not to place undue reliance on any forward-looking statements.
Contact Information:
INVESTOR CONTACTS
John Woolford
(443) 213-0506
Email Contact
Keith A. Goldan
Vice President, Chief Financial Officer
NuPathe Inc.
(484) 567-0130
MEDIA CONTACT
Jennifer Guinan
Sage Strategic Marketing
(610) 410-8111
Email Contact
SOURCE: NuPathe Inc.
http://www2.marketwire.com/mw/emailprcntct?id=CE9621D87EEFE792
http://www2.marketwire.com/mw/emailprcntct?id=8FF39745074A48B3
News Pulse
Top Stories
What Scottrade Customers are Reading...
1008
Views
Ford Motor Large Insider Trad…
COMTEX - 27 days 9 hours 17 minutes ago.873
Views
Dividends From Annaly and Cyp…
COMTEX - 5 days 10 hours 1 minutes ago.718
Views
US HOT STOCKS: Caterpillar, …
DJNF - 11 days 4 hours 41 minutes ago.453
Views
DryShips Buys OceanFreight F…
DJNF - 7 days 9 hours 54 minutes ago.305
Views
Sirius XM 2Q Net Soars, Rais…
DJNF - 10 hours 23 minutes ago.
View More Headlines
.
The whole market took a dive, but Path outstripped the market...hopefully the rest of the month will be better.
PATH seems to be taking it on the chin today!
So far still holding all ... only thing I have lost is a good pair Depends...clean up aisle 6
I bought a few more down here. I hope down here is the new bottom and we start to climb back up soon!
$PATH 13.1% of float is short. If it runs before PDUFA their nuts will be in a vise. LOL
And that did not happen
I am looking at the 6.20 see if we get a bounce
Trying to decide if I want to cut my losses or average down and hold on longer into August???
Sho-Nuff
The way I am seeing and understanding is that we should start to see PATH climb as we move to the August 29 approval date.
Might even see something move it up greatly before then.
JMO,
Sho-Nuff
I followed you today
I grabbed a position in PATH today. Hoping as we move into August that PATH will lead to higher ground for the PPS!
JMO,
Sho-Nuff
NuPathe, Inc. (PATH) has a PDUFA date of August 29 for Zelrix, its transdermal patch for the treatment of migraines. The active ingredient in Zelrix is sumatriptan, the most commonly prescribed drug for migraine treatment. The sumatriptan is administered via NuPathe’s proprietary SmartRelief technology, a controlled delivery technology that uses a mild electrical current to actively deliver medication through the skin in a process called iontophoresis. Not only would an approval provide NuPathe with the obvious financials of a marketed drug, but it would also legitimize its SmartRelief technology, which would likely be utilized to deliver other drugs for the company or for potential licensees. More information on Zelrix may be viewed at the company’s website.
http://seekingalpha.com/article/276594-biotech-catalysts-for-third-quarter?source=yahoo
NuPathe(PATH_)
The event: FDA approval decision for the migraine patch Zelrix.
The timeline: FDA is expected to make its approval decision on Aug. 29.
The stakes: If approved, Zelrix would be NuPathe's first commercially marketed product. Zelrix is a battery-operated patch that pushes a steady stream of the commonly used migraine medicine sumatriptan through the skin and into the patient's bloodstream.
http://www.thestreet.com/story/11180428/2/more-hot-biotech-trades-for-second-half-2011.html
Agree with you! time will give the profits!
http://seekingalpha.com/article/276594-biotech-catalysts-for-third-quarter
No brainer for PATH..Buy and hold..
Get on the train before it pulls out of the station.... I just loaded up
i jumped in last week too..this should be interesting
~~ i'm here ~ hello :)
i just got some path!
$heff's pick of yesterday!
i love low float play!
good luck to us =^.^=
Hello....anyone home? I'm sure this will heat up as we fet closer to August.
Followers
|
36
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
724
|
Created
|
10/07/10
|
Type
|
Free
|
Moderators |
Our first commercial product is Zecuity™ sumatriptan iontophoretic transdermal system (patch) for the acute treatment of migraine. We are seeking commercialization partners in the U.S. and worldwide.
In addition, we have a strong pipeline based on our biodegradable implant technology that allows us to deliver therapeutic levels of medication over a period of months with a single dose. NP201, for the continuous symptomatic treatment of Parkinson's disease, utilizes a leading FDA-approved dopamine agonist and is being developed to provide up to two months of continuous delivery. NP202 is being developed to address patient noncompliance, a long-standing problem in the treatment of schizophrenia and bipolar disorder, by providing three months of continuous delivery of risperidone, an atypical antipsychotic. We are seeking a development partner for each of these candidates to capitalize on their commercial potential worldwide.
Beyond our current product pipeline, we intend to be a leader in the rapidly growing transdermal patch market with our active SmartRelief technology, delivering innovative solutions across a range of therapeutic areas.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |